Prostate cancer immunotherapy extends survival, study shows

Patients with Gleason scores =7 receiving an investigational form of immunotherapy for prostate cancer showed a significant survival advantage.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria